Characteristics
|
PFS
|
OS
|
---|
HR (95 % CI)
|
P value
|
HR (95 % CI)
|
P value
|
---|
Gender (Female vs Male)
|
1.936 (1.044–3.590)
|
0.036
|
2.039 (1.178–3.531)
|
0.011
|
Age (≥65 vs <65)
|
0.381 (0.175–0.831)
|
0.015
|
0.481 (0.236–0.980)
|
0.044
|
Clinical T stage (T3-4 vs T2)
|
0.928 (0.507–1.697)
|
0.808
|
1.010 (0.575–1.776)
|
0.972
|
Clinical TNM stage (III vs II)
|
0.697 (0.389–1.249)
|
0.226
|
0.692 (0.404–1.185)
|
0.180
|
ypN stage (N1vs N0)
|
0.427 (0.248–0.734)
|
0.002
|
0.406 (0.240–0.686)
|
0.001
|
- Note: HR: hazard ratio, CI: confidence interval, ypN: post-therapy pathologic lymph node status; pCR: pathologic complete response; ypT0N1: pathologic complete response in tumor but residual lymph node metastasis after neoadjuvant radiotherapy and surgery